ClinicalTrials.gg
CompletedNCT00720577LEAPUpdated May 14, 2021

Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.

An Early Phase 1 interventional study of Simvastatin and Losartan in Peripheral Arterial Disease, sponsored by Medtronic Endovascular. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Medtronic Endovascular (part of Medtronic) · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Peripheral Arterial Disease by Medtronic — 1 open to participants now, 1 under way, none of them phase 3. Peripheral Arterial Disease · Medtronic.

Enrollment
6th of 17
164 · median 121
Started
2005
the only one that year
Phase 1
Only one
of the 22
Registered
2nd of 22
by date

Among the 22 studies in Peripheral Arterial Disease by Medtronic, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2005, is the only one in phase 1, and was the 2nd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 22 studies in Peripheral Arterial Disease by Medtronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Peripheral Arterial Disease by Medtronic, or all of them as a file.
02

Study summary

Part A. The purpose of this study is to assess the effects of 6 weeks of treatment with, simvastatin, losartan or pioglitazone compared to placebo on the RNA expression profile of lower extremity peripheral arterial atherosclerotic plaque. Part B. The effect of simvastatin, losartan or pioglitazone compared to placebo on protein and lipid biomarkers in lower extremity peripheral arterial atherosclerotic plaque.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled, 6 week study. The study consists of 3 separate sub-studies in which patients undergoing bilateral lower extremity peripheral artery atherectomy will receive one of three FDA approved drugs known to have beneficial effect on the risk of cardiovascular disease. Patients will be selected for the particular sub-study based on a series of entry criteria and then randomized to the particular agent or placebo for 6-weeks.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Peripheral Arterial Disease
  • PAD
  • Lower extremity peripheral arterial atherosclerotic plaque
  • RNA Expression
  • Lipid Biomarkers
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women =90 years of age.
  • Bilateral lower extremity PAD requiring revascularization. Both extremities must have at least 1denovo atherosclerotic lesion
  • Able to space bilateral atherectomy procedures by at least 6 weeks.
  • Willing to provide to participation in genetic studies.
  • Simvastatin Substudy
  • LDL-C >100 mg/dL and \<250 mg/dL TG\<350 mg/dL
  • Not currently receiving or having taken a statin (simvastatin, lovastatin, rosuvastatin, atorvastatin, or pravastatin) or a combination product containing a statin for the previous 3 months.
  • Losartan Substudy
  • Diagnosis of hypertension with systolic blood pressure >120 mm Hg but \<160 mm Hg, and diastolic blood pressure >80 mm Hg but \<100 mm Hg.
  • Not currently receiving or having taken an ACEi or ARB.
  • Pioglitazone Substudy
  • Type II diabetes mellitus
  • >5.5% and \< 8.5%
  • Otherwise on a stable glucose lowering regimen where no changes are expected in oral regimen, or where no changes in insulin doses of more than 10 U are expected.
  • Not currently receiving or having taken a thiazolidinedione (rosiglitazone or pioglitazone) or a combination product containing a thiazolidinedione or the previous 12 months.

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant, breast-feeding, or expecting to conceive during the study including the 14-day post study follow-up.
  • current condition, therapy, lab abnormality, mental legal incapacitation that in the investigator's judgment might confound the results of the study.
  • Patient is currently participating in or has participated in a study with an compound within 30 days of Visit 1.
  • Patient has donated and/or received blood (including phlebotomy of >300 mL) within 2 months prior to study.
  • Surgery or significant trauma within 2 months prior to Visit 1.
  • Patient is a user of recreational or illicit drugs or has had a recent history \<1yr drug/alcohol abuse>2 alcoholic drinks per day).
  • Patient was \<80% compliant with dosing during the placebo run-in period AND, in the opinion of the investigator, believed to be unable to maintain at least an 80% compliance with dosing during the active study dosing period.
  • Patient has history of myocardial infarction, stroke, coronary artery bypass surgery or other coronary, carotid, or cerebral revascularization procedure,unstable angina, or angioplasty within 1 month of Visit 1. - Patient has chronic heart failure defined by NYHA) Classes III or IV.
  • Known AV conduction disturbances or arrhythmias
  • Patient has unstable hypertension (e.g., sitting systolic blood pressure >160 mm Hg or diastolic >100 mm Hg) at Visit 1.
  • Any known clinically important bleeding or disorder.
  • Patient has history of ileal bypass, gastric bypass, other significant condition associated with malabsorption.
  • Patient is or positive.
  • Patients with significantly elevated TSH at Visit 1 may be entered after consultation with and approval by the SPONSOR. Patients with a history of hypothyroidism, who are on a stable dose of thyroxine with normal TSH level at Visit 1 may be included.
  • Patients on cyclical estrogen medications (Estrogen Replacement Therapy ERT] or oral ). Patients on non-cyclical estrogen replacement therapy or Selective Estrogen Receptor Modulator (SERM) may be included, but must be on a stable dose for at least 8 weeks prior.
  • Patients with active neoplastic disease which compromises their general health, or who currently require chemotherapy or radiation therapy, or who have completed chemotherapy or radiation therapy within 3 months prior.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
164 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Simvastatin

  • Active comparator
    2

    Drug: Losartan

  • Active comparator
    3

    Drug: Pioglitazone

Interventions

  • 40 Mg. tablet, 1 tablet daily

    Also known as: HMG-CoA reductase

  • 50 mg., tablets, 1 tablet once daily

    Also known as: Cozaar

  • 30 mg, tablet, 1 tablet once daily

    Also known as: Systematic (IUPAC)

06

What researchers measure

Primary outcomes

  1. Evaluate RNA expression profiles, protein and lipid biomarkers, and gene expression profiling on pts receiving simvastatin, losartan or pioglitazone.

    Time frame: 6 weeks

Secondary outcomes

  1. Evaluate plaque characteristics in 3 patient subsets and Left and Right extremity comparisons.

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jul 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2008
First posted
Jul 23, 2008
Start
Dec 2005
Primary completionActual
Jul 2007
CompletionActual
Aug 2007
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00720577
Responsible party
Sponsor
First posted
Jul 23, 2008
Start date
Dec 2005
Primary completion
Jul 2007
Completion
Aug 2007
Last update
May 14, 2021

Study contacts

David Kandzari, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simvastatin · Losartan · Pioglitazone

Start the discussion